Zenith Epigenetics and Cencora have signed an agreement to expedite the commercialisation of Zenith’s ZEN-3694 programme.

This programme deploys an advanced epigenetic approach to synergistically enhance the efficacy of existing cancer drugs.

Cencora will offer a range of services to plan the market launch of ZEN-3694.

Initially, the focus will be on assessing regulatory and market access to provide insights into potential opportunities and obstacles around its introduction.

These insights will help customise the development of ZEN-3694 and create patient access and adherence programmes for the entire healthcare system.

Zenith chairman, founder and CEO Donald McCaffrey stated: “For a product with the immense capabilities ZEN-3694 has, we knew we needed a partner with immeasurable experience across healthcare, unmatched distribution capabilities and a global impact.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

“Cencora emerged as the best partner to lead the commercial and distribution strategy for ZEN-3694 with innovation, strategic thinking and careful planning around patient access and the patient experience.”

The compound is currently under clinical development for multiple oncologic indications, with a number of studies sponsored by NCI through the NCI-Zenith co-operative research and development agreement (CRADA) and other CRADAs involving NCI and its partners.

Partners and collaborators include Astellas, BMS, Eli Lilly, GSK, Merck, Pfizer and Syndax.

The programme is also supported by several further collaborators and partners, including Dana Farber – Harvard, MD Anderson, Memorial Sloan Kettering, the National Cancer Institute, the National Institute of Health, UCSF and Yale.

Cencora International Commercialisation senior vice-president Sandra Anderson stated: “We are thrilled to support Zenith’s pre-commercial launch preparations and will provide the solutions they need to help them accelerate time-to-market and maximise commercial success.”